Keros CEO to Present at Goldman Sachs Healthcare Conference
Event summary
- Keros Therapeutics CEO Jasbir S. Seehra to participate in fireside chat at Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026.
- Live audio webcast available at specified URL, archived replay accessible for 90 days post-event.
- Keros focuses on TGF-ß protein signaling disorders, with lead candidates rinvatercept (Duchenne muscular dystrophy, ALS) and elritercept (cytopenias).
The big picture
Keros' participation in the Goldman Sachs conference underscores its push for visibility amid a competitive biotech landscape focused on protein signaling disorders. The event provides a platform to highlight its pipeline, particularly as it navigates the clinical-stage challenges of its lead candidates. The broader industry trend of targeting TGF-ß pathways for therapeutic intervention positions Keros within a niche but growing segment of the biopharmaceutical market.
What we're watching
- Pipeline Progress
- How Keros advances its lead candidates through clinical trials and regulatory milestones.
- Investor Sentiment
- Whether the conference presentation shifts market perception of Keros' strategic direction.
- Competitive Positioning
- The pace at which Keros differentiates itself in the TGF-ß protein signaling space.
Related topics